Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AnGes, Osaka Univ. to Pair Up to Develop DNA Vaccines for COVID-19
March 6, 2020
- Chugai, Teijin Suffer Hefty 9% Cuts in 2020 Drug Price Revision: Jiho Poll
March 6, 2020
- Keytruda Remains Top-Seller in February Drug Ranking: Encise
March 6, 2020
- Takeda Joins Fight against COVID-19, Eyes Plasma Product Launch in 9-18 Months
March 5, 2020
- Braftovi/Mektovi Filed for Colorectal Cancer in Japan: Ono
March 5, 2020
- Takeda Closes Non-Core Asset Divestment to Stada
March 5, 2020
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Asahi Kasei Completes Acquisition of Veloxis
March 5, 2020
- Sumitomo Dainippon Creates Chief Scientific Officer Post to Optimize Portfolio
March 4, 2020
- Shionogi’s Fetcroja Bags EU Panel Nod
March 4, 2020
- Sawai Refrains from Sales Reps' Doctor Visits Through March 13
March 4, 2020
- GE Healthcare Completes Takeover of Japan Licenses for 4 Imaging Agents from Daiichi Sankyo
March 4, 2020
- Kaken’s Efinaconazole Launched in Hong Kong
March 4, 2020
- Vital-Net to Create 20-Strong Team of “Regenerative Medicine Liaisons”
March 3, 2020
- Takeda’s ALK Drug Alunbrig Earns EU Backing for 1st Line NSCLC
March 3, 2020
- Takeda to Sell Latin American Non-Core Assets to Brazil’s Hypera Pharma
March 3, 2020
- Otsuka to Copromote Novartis’ Approval-Pending Entresto in Japan
March 3, 2020
- Sumitomo Dainippon Invests in Oncology Venture Fund
March 3, 2020
- Fujifilm’s US Subsidiary to Launch New iPS Cell Production Facility
March 3, 2020
- Toho Forges Capital Alliance with Kringle Pharma for Hepatocyte Growth Factor Development
March 3, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…